CAS No.: | 1415456-99-3 |
---|---|
Formula: | C194h312n54o59s2 |
Type: | Pharmaceutical Intermediates |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Products Name: Cagrilintide
CAS No.: 1415456-99-3
Purity: >99.0%
Appearance: White Lyophilized powder
Reconstitution: Required
Storage:After reconstitution store at 2°C - 8°C
Product Name: | Cagrilintide | Cas No. | 1415456-99-3 |
Purity: | 99% | Formula weight: | 4113.57754 |
Package: | Box | Molecular formula: | C187h291n45o59 |
MOQ: | 1 Gram or 1 Box | EINECS: | 203-405-2 |
Transportation: | By Air | Grade Standard | Top Quality |
Sample | Availiable | Shelf Life | 2 Years |
CagriSema injection is a combination therapy that includes the glucagon-like peptide-1 (GL-1) receptor agonist sema and the long-acting amylin analog cagrilintide . The therapy has weight loss benefits, but the effect on glycated hemoglobin (HbA1c) is unclear.
The 83rd American Diabetes Association Scientific Conference 2023 (ADA 2023) will be held in San Diego, USA on June 23, local time. A study was announced during the meeting, which evaluated the effectiveness and safety of CagriSema (sema combined with canaglitide) in patients with type 2 diabetes. Results showed that in patients with type 2 diabetes, treatment with CagriSema improved glycemic control and resulted in significant weight loss compared with sema or canaglitide monotherapy and was well tolerated with no new safety concerns. sexual signals.
This multi-center, double-blind, phase 2 trial included a total of 92 patients with a body mass index (BMI) ≥27 kg/m2 from 17 research centers in the United States from August 2 to October 18, 2021, who received metformin with or without metformin. Adult patients with type 2 diabetes (HbA1c 7.5%~10.0%) treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors were randomly assigned in a 1:1:1 ratio to receive a weekly subcutaneous injection of CagriSema ( n=31), sema (n=31), or canaglitide (n=30) (dose escalation to 2.4 mg over 16 weeks) for 32 weeks. Of these patients, 59 (64%) were male. The average age of patients was 58 years old. The primary endpoint of the study was the change in HbA1c from baseline. Secondary endpoints were body weight, fasting glucose, continuous glucose monitoring (CGM) parameters and safety.
1. Product Quality Assurance: We maintain stringent quality standards. Contact us for quality-related issues.
2. Returns and Refunds: Notify us of damaged or incorrect products. Refer to our Returns and Refunds Policy.
3. Technical Support: Reach our technical support team for assistance.
4. Order Tracking: Receive tracking information for your order.
5. Customer Feedback: Share your feedback with us.
6. Warranty Information: Some products may have warranties.
7. Updates and Notifications: Subscribe to our newsletter for updates.
Welcome to be our distinguished customer, please do not hesitate to contact us!